Liaocheng

Researchers are comparing the effects and safety of two drugs, GQ1005 and Trastuzumab Emtansine T-DM1, in adults with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. This phase III trial focuses on patients who have previously been treated with trastuzumab and taxane. The study aims to understand which treatment might better manage this advanced form of breast cancer. Participants will be randomly assigned to receive either GQ1005 or T-DM1. Both drugs are given through intravenous infusions every 21 days. About 228 patients will take part, and the treatments will continue to be monitored over approximately 24 months to assess their impact on cancer progression and safety. During the study, participants will have regular assessments including scans to measure tumor size and blood tests to monitor the drugs in their system. Researchers will track how long patients live without cancer progression, overall survival, response rates, adverse events, and quality of life changes. These evaluations will help understand the benefits and risks of each treatment over time.

Researchers are evaluating the effectiveness and safety of Yangxinshi tablets for patients with chronic coronary syndrome CCS. This is a prospective, multicenter, randomized, open-label, blinded-endpoint clinical trial including 1200 CCS patients. The study is designed to assess exercise capacity and other health outcomes in this population. Participants will be randomly assigned in a 31 ratio to either an experimental group or a control group. The experimental group will receive Yangxinshi tablets three times a day three tablets each time in addition to their basic medication, while the control group will receive only their basic medication. The treatment period for both groups is 24 weeks. During the study, researchers will measure the primary outcome of the 6-minute walking distance 6MWD after 24 weeks of treatment. Secondary outcomes include assessments using the Borg scale and monitoring of major adverse cardiovascular and cerebrovascular events MACCE at multiple time points during treatment. Participants will be monitored for safety and efficacy throughout the 24-week treatment period.